From: Gene-expression signature functional annotation of breast cancer tumours in function of age
Patients’ group (years and [n]) | n 2378 | ≤40 (n = 345) | 40 < x < 70 (n = 1667) | ≥70 (n = 366) | p-value | |
---|---|---|---|---|---|---|
Age (years) | Â | Â | Â | Â | Â | Â |
 | Median (IQR) | 54 (45–64) | 37 (34–39) | 54 (47–61) | 74 (72–80) |  |
ER status | Â | Â | Â | Â | Â | Â |
 | Positive | 1671 (71 %) | 199 (58 %) | 1170 (71 %) | 302 (83 %) | <0.0001 |
 | Negative | 681 (29 %) | 143 (42 %) | 477 (29 %) | 61 (17 %) |  |
HER2 status | Â | Â | Â | Â | Â | Â |
 | Positive | 136 (14 %) | 28 (19 %) | 89 (13 %) | 19 (17 %) | 0.4862 |
 | Negative | 808 (86 %) | 121 (81 %) | 592 (87 %) | 95 (83 %) |  |
Nodal status | Â | Â | Â | Â | Â | Â |
 | Positive | 882 (43 %) | 130 (49 %) | 603 (42 %) | 149 (44 %) | 0.4010 |
 | Negative | 1172 (57 %) | 138 (51 %) | 847 (58 %) | 187 (56 %) |  |
SBR grade | Â | Â | Â | Â | Â | Â |
 | 1 | 302 (17 %) | 15 (6 %) | 223 (17 %) | 64 (22 %) | <0.0001 |
 | 2 | 770 (42 %) | 83 (36 %) | 561 (44 %) | 126 (43 %) |  |
 | 3 | 742 (41 %) | 134 (58 %) | 504 (39 %) | 104 (35 %) |  |
Tumour size | Â | Â | Â | Â | Â | Â |
 | ≤20 mm | 626 (46 %) | 57 (44 %) | 458 (48 %) | 111 (42 %) | 0.3993 |
 | >20 mm | 723 (54 %) | 72 (56 %) | 499 (52 %) | 152 (58 %) |  |